AZD 8294
Latest Information Update: 03 Apr 2006
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lipid metabolism disorders
Most Recent Events
- 02 Feb 2006 Discontinued - Preclinical for Lipid metabolism disorders in Europe (unspecified route)
- 20 Jun 2005 This compound is still in active development
- 02 Oct 2003 Preclinical trials in Lipid metabolism disorders in Europe (unspecified route)